Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Costs vary significantly by pharmacy, strength, and quantity
Standard qualification criteria include: BMI 30 kg/m (obesity) regardless of comorbidities BMI 27 kg/m (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease Age 18 years or older (Wegovy and Saxenda are also approved for adolescents aged 12 and above
The neuroprotective effect of adenosine is primarily mediated by A(1) receptors and the inhibition of glutamatergic excitotoxicity
Participants, drawn from health records of nearly 140,000 patients in Canada, were matched for socioeconomic status and a long list of conditions in addition to diabetes
